Roivant Sciences Ltd. $ROIV Shares Purchased by Nicholas Investment Partners LP

Nicholas Investment Partners LP boosted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 13.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 279,856 shares of the company’s stock after acquiring an additional 34,235 shares during the quarter. Nicholas Investment Partners LP’s holdings in Roivant Sciences were worth $6,073,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. raised its holdings in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after acquiring an additional 1,148 shares in the last quarter. Allworth Financial LP raised its holdings in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares in the last quarter. Bessemer Group Inc. raised its holdings in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. Finally, Kestra Advisory Services LLC acquired a new stake in Roivant Sciences in the fourth quarter valued at approximately $47,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Up 1.0%

Shares of Roivant Sciences stock opened at $30.04 on Friday. The firm has a market capitalization of $21.61 billion, a P/E ratio of -50.07 and a beta of 1.13. Roivant Sciences Ltd. has a 52 week low of $10.70 and a 52 week high of $32.79. The firm’s 50 day moving average is $28.95 and its two-hundred day moving average is $25.98.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same period last year, the firm posted ($0.29) earnings per share. As a group, research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Guggenheim raised their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. HC Wainwright reiterated a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $33.59.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $48,827,417.01. This trade represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Jennifer Humes sold 13,538 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total transaction of $384,073.06. Following the transaction, the chief accounting officer owned 84,191 shares in the company, valued at approximately $2,388,498.67. This trade represents a 13.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 945,173 shares of company stock valued at $27,654,456. 10.80% of the stock is currently owned by insiders.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.